Sorrento Therapeutics (SRNE) Publishes an Abivertinib Teaser Entitled "Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases"

November 29, 2021 9:03 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases” (“Abivertinib Teaser”). Sorrento intends to use the Abivertinib Teaser to engage in discussions with interested third parties in the pharmaceutical industry.

The key highlights of the Abivertinib Teaser are outlined below:

  • Abivertinib for COVID-19 (Two Phase 2 trials Completed)
    • 100 mg once-a-day oral capsule for hospitalized COVID-19 patients
    • US trial (N=96) and Brazil trial (N=400)

For Severe Ordinal Scale (OS) Category 5 COVID-19 Patients (“At-Risk Group”) identified to be beneficial with Abivertinib treatment at Day 28 (D28):

  • Abivertinib reduced the risk of death or respiratory failure:
    • by 48% in US trial (death or respiratory failure: 21.7% in the Abivertinib group vs. 41.7% in the placebo plus Standard of Care (SoC) control group)
    • by 45% in Brazil trial (death or respiratory failure: 30.4% Abivertinib vs. 55.6% placebo plus SoC controls)
  • Abivertinib reduced the ICU stay:
    • by 2 days in the US trial (8.6 days average stay in ICU in Abivertinib group vs. 10.6 days in placebo plus SoC control group)
  • Abivertinib for Cancer IndicationsNSCLC (Pivotal Trial: N=229) - Among 209 response evaluable NSCLC patients who developed resistance to first line Tyrosine Kinase Inhibitors (TKIs):
  • 93.3% (n/N: 195/209) subjects achieved tumor shrinkage at target lesions
  • 57.4% (n/N: 120/209) subjects achieved the best ORR (confirmed + unconfirmed PR)
  • 52.2% (n/N: 109/209) subjects achieved confirmed PR
  • 24.9 months OS A photo accompanying this announcement is available at B-Cell Lymphoma (Phase 1/2 Trial) (as of 08/28/2020)
  • 63.6% ORR (n/N: 14/22)
  • 95.5% DCR (n/N: 21/22)
  • 19.7 Months PFS
  • Abivertinib – A Broad Pipeline for Cancer, COVID-19 and Autoimmune Diseases ($61B Market)

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Related Entities